Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
Foghorn Therapeutics Inc. logo

NASDAQ · FHTX

Foghorn Therapeutics Inc.

Healthcare · Biotechnology

$2.08

Down-$0.01 (-0.48%)

Updated Oct 31, 2026, 2:07 AM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
252.77M
P/E ratio
-3.73
Dividend yield
0.00%
52-week range
$1.79 – $7.61
Volume
555.61K
Avg. volume
207.49K

Price performance · FHTX

FHTX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

FHTX closed at $2.08 after 21 trading sessions, up 2.97% for the selected period.

Last close
$2.08
Period change
+2.97%
Period low
$1.85
Period high
$2.13
Daily close
View OHLC price history
FHTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$2.08$2.09$2.005$2.08555.61K
Oct 29, 2026$2.16$2.20$2.06$2.09396.99K
Oct 28, 2026$2.04$2.13$2.03$2.13483.37K
Oct 27, 2026$2.04$2.09$1.99$2.05874.69K
Oct 26, 2026$1.99$2.06$1.93$2.05509.75K
Oct 23, 2026$1.97$2.035$1.90$2.00486.82K
Oct 22, 2026$2.00$2.09$1.985$2.01301.05K
Oct 21, 2026$2.02$2.10$1.99$2.04819.59K
Oct 20, 2026$1.87$2.065$1.8699$2.01555.1K
Oct 19, 2026$1.81$1.91$1.80$1.87440.85K
Oct 16, 2026$1.81$1.90$1.81$1.85981.3K
Oct 15, 2026$1.87$1.91$1.82$1.89349.34K
Oct 14, 2026$1.85$1.8899$1.80$1.851.07M
Oct 13, 2026$1.945$1.95$1.84$1.85852.39K
Oct 12, 2026$1.98$2.00$1.94$1.95586.3K
Oct 9, 2026$1.96$2.081$1.945$2.00646.95K
Oct 8, 2026$2.05$2.14$1.885$1.991.23M
Oct 7, 2026$1.92$2.15$1.9062$2.09917.11K
Oct 6, 2026$2.00$2.02$1.835$1.97984.69K
Oct 5, 2026$2.03$2.12$1.98$2.00987.96K
Oct 2, 2026$2.91$2.91$1.99$2.022.55M

Latest FHTX news

The latest Smart Investors Daily articles mentioning FHTX.

Stock researchCompany · Overview

FHTX research

Overview

Company profile and research snapshot.

Company profile

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$12.00
Implied upside
—
Analysts
14
FHTX recent ratings
DateFirmRatingTarget
Oct 2, 2026BTIGNeutral—
Oct 2, 2026WedbushNeutral—
Oct 2, 2026TD CowenHold—
Oct 2, 2026GuggenheimBuy—
Oct 2, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

Foghorn Therapeutics (FHTX) Stock Fair Value Moves Lower After Pipeline And Lilly Reset

The fair value estimate for Foghorn Therapeutics has been reset from US$6.00 to about US$4.17, reflecting a meaningful change in how the stock is currently modeled. This move lines up with recent Street commentary that factors in the FHD-909 setback, the end of the Eli Lilly collaboration, and a renewed focus on earlier stage programs and a leaner cost base. As you read on, you will see how analysts are updating their narrative and what to watch as the story continues to evolve. Analyst Price...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By